Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2020 Sep 16;5:194. doi: 10.1038/s41392-020-00232-5

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2020

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

PMC Copyright notice

Fig. 4 — Analysis of EPO receptor (R) levels and the influence of EPOR blocker on DC and T cells. a Effect of CEOP on EPOR mRNA levels in DC and CD4⁺ T cells was examined by qPCR analysis. b Effect of CEOP on EPOR protein levels in DC and CD4⁺ T cells was detected by western blotting. c Western Blot analysis of EPOR protein levels after treatment of cells with the selective PI3K/AKT signaling pathway inhibitor LY294002. d DC cells were treated with CEOP, EPOR blocker, or CEOP+EPOR blocker, as indicated. The expression of CD11b, CD80, CD86, and MHC-II in DC were evaluated by flow cytometric analysis. e qPCR analysis of the mRNA levels of IL-2, IFN-γ, TNF-α, IL-4, IL-5, IL-10 and IL-13 in CD4⁺ T cells treated with the CEOP, EPOR blocker, or CEOP+EPOR blocker, as indicated. f Western Blot analysis of IL-2, IFN-γ, TNF-α, IL-4, IL-5, IL-10, and IL-13 protein expression in CD4⁺ T cells treated with EPOR blocker, EPOR blocker + CEPO, or CEOP alone. g Influence of EPOR blocker, CEPO alone, and EPOR blocker + CEPO on the Th1, Th2, and Th1/Th2 ratio was determined by flow cytometry. Images shown are representative of at least three independent experiments, data are expressed as mean ± SEM (*p < 0.05, p values were calculated by Student’s t-test)